Payment overview · 2025
General Payments
$401.61
17 reported records · 9 companies
Healthcare provider profile · identity verified
Elizabeth Whitaker Brown, MSN, RN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BROOKHAVEN, MS · NPI 1336422021
Verified facts
What the public records show
CMS Open Payments records show Elizabeth Whitaker Brown, MSN, RN received $401.61 in general payments during 2025 across 17 reported records.
Corcept Therapeutics accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $154.05 | 38.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.93 | 17.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.68 | 12.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.81 | 7.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.69 | 6.2% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $19.62 | 4.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.40 | 4.6% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $16.75 | 4.2% | 1 | 2025 |
| Ortho-Clinical Diagnostics, Inc. | Unresolved — no canonical attribution shown | $15.68 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.61 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $154.05 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.93 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $69.93 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| VITROS Normalized: vitros |
Device | Ortho-Clinical Diagnostics, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 251 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 73 |
| Gabapentin | Gabapentin | 210 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 183 | 53 |
| Omeprazole | Omeprazole | 143 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 41 |
| Lisinopril | Lisinopril | 112 | 35 |
| Metformin Hcl | Metformin Hcl | 101 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 27 |
| Eliquis | Apixaban | 96 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 33 |
| Furosemide | Furosemide | 94 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 24 |
| Losartan Potassium | Losartan Potassium | 92 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 27 |
| Buspirone Hcl | Buspirone Hcl | 87 | 28 |
| Alendronate Sodium | Alendronate Sodium | 83 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Ozempic | Semaglutide | 77 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 13 |
| Allopurinol | Allopurinol | 70 | 24 |
| Potassium Chloride | Potassium Chloride | 70 | 30 |
| Trazodone Hcl | Trazodone Hcl | 68 | 26 |
| Tramadol Hcl | Tramadol Hcl | 67 | 18 |
| Mirtazapine | Mirtazapine | 64 | 13 |
| Carvedilol | Carvedilol | 63 | 20 |
| Meloxicam | Meloxicam | 60 | 26 |
| Alprazolam | Alprazolam | 59 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 16 |
| Famotidine | Famotidine | 56 | 21 |
| Metformin Hcl Er | Metformin Hcl | 56 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Jardiance | Empagliflozin | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Montelukast Sodium | Montelukast Sodium | 46 | 16 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 41 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 11 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 14 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 15 |
| Simvastatin | Simvastatin | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 14 |
| Colchicine | Colchicine | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Prednisone | Prednisone | 23 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.61 · 17 records | Corcept Therapeutics | AIRSUPRA, INSPIRE, KISUNLA, Korlym, MOUNJARO, NURTEC ODT, QULIPTA, QUTENZA, UBRELVY, VITROS, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error